Squarepoint Ops LLC Grows Stock Position in Replimune Group, Inc. $REPL

Squarepoint Ops LLC lifted its position in Replimune Group, Inc. (NASDAQ:REPL) by 394.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 67,929 shares of the company’s stock after acquiring an additional 54,178 shares during the period. Squarepoint Ops LLC owned 0.09% of Replimune Group worth $631,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after purchasing an additional 1,879 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Replimune Group in the second quarter valued at about $69,000. Tower Research Capital LLC TRC lifted its stake in shares of Replimune Group by 2,020.8% in the second quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company’s stock worth $90,000 after buying an additional 9,235 shares in the last quarter. AlphaQuest LLC boosted its position in Replimune Group by 99.9% during the second quarter. AlphaQuest LLC now owns 9,857 shares of the company’s stock worth $92,000 after acquiring an additional 4,925 shares during the last quarter. Finally, Letko Brosseau & Associates Inc. purchased a new stake in Replimune Group during the 2nd quarter valued at about $100,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Replimune Group

In related news, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Konstantinos Xynos sold 7,248 shares of Replimune Group stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $9.10, for a total transaction of $65,956.80. Following the completion of the sale, the insider owned 139,685 shares of the company’s stock, valued at $1,271,133.50. This trade represents a 4.93% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is owned by corporate insiders.

Replimune Group Price Performance

REPL stock opened at $9.72 on Wednesday. Replimune Group, Inc. has a 52-week low of $2.68 and a 52-week high of $14.80. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.26. The stock has a market cap of $762.44 million, a price-to-earnings ratio of -2.81 and a beta of 0.66. The business has a fifty day moving average of $9.18 and a two-hundred day moving average of $7.62.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). As a group, research analysts anticipate that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on REPL. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $4.00 to $18.00 in a research note on Monday, October 20th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target for the company in a report on Monday, October 20th. Leerink Partnrs upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 20th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 target price for the company in a report on Monday, October 20th. Finally, HC Wainwright raised Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 target price for the company in a research note on Monday, October 27th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.75.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.